Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolite Profile of [14C]-Paxalisib in Healthy Males
NCT05012670Phase 1Completed
- Sponsor
- Kazia Therapeutics
- Start
- Aug 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paxalisib in glioblastoma (GBM), sponsored by Kazia Therapeutics. Primary endpoints: Mass Balance Recovery, Plasma Metabolite Profiling and Identification and 2 more. Started Aug 2021; status: completed.
02
Drugs
paxalisib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05012670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05012670.